Sugi Predict

Sugi Predict / Compounds / SCHEMBL2000376

SCHEMBL2000376

SCHEMBL2000376

CC(NC(=O)OC(C)(C)C)C1CCNCC1

nearest known ligand 0.41

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ CA1 P00915 3/20 0.41
▸ CA2 P00918 3/20 0.41
▸ CA7 P43166 1/20 0.41
▸ KMT2A Q03164 1/20 0.40
▸ CTSK P43235 7/20 0.38
▸ CTSS P25774 4/20 0.38
▸ CYP2D6 P10635 1/20 0.38
▸ ELANE P08246 1/20 0.36
▸ CA12 O43570 3/20 0.36
▸ CA14 Q9ULX7 1/20 0.36
▸ AAK1 Q2M2I8 1/20 0.35
▸ MMP2 P08253 2/20 0.35
▸ CA9 Q16790 2/20 0.35
▸ BTK Q06187 1/20 0.35
▸ CTSL P07711 1/20 0.35
▸ CTSB P07858 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17946227 1.00 CA1 (0.41) CA1CA2CA7KMT2ACTSK
SCHEMBL4024512 0.91 CA1 (0.40) CA1CA2CA7KMT2ACTSK
SCHEMBL4511453 0.91 CA1 (0.40) CA1CA2CA7KMT2ACTSK
SCHEMBL4511728 0.91 CA1 (0.40) CA1CA2CA7KMT2ACTSK
SCHEMBL3188762 0.91 CA1 (0.40) CA1CA2CA7KMT2ACTSK
SCHEMBL3188755 0.91 CA1 (0.40) CA1CA2CA7KMT2ACTSK
SCHEMBL4514488 0.91 CA1 (0.40) CA1CA2CA7KMT2ACTSK
SCHEMBL7506420 0.91 CA1 (0.40) CA1CA2CA7KMT2ACTSK
SCHEMBL4509851 0.91 CA1 (0.40) CA1CA2CA7KMT2ACTSK
SCHEMBL2002713 0.91 CA1 (0.40) CA1CA2CA7KMT2ACTSK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12503452-B2 Antimicrobial compounds and methods CURZA GLOBAL, LLC (US) 2025-12-23 — — US disclosed
US-20240336593-A1 Compound Having Antitumor Activity And Use Thereof INNOVSTONE THERAPEUTICS LIMITED (CN) 2024-10-10 — — US disclosed
EP-3654968-B1 METALLO-BETA-LACTAMASE INHIBITORS AND METHODS OF USE THEREOF MERCK SHARP & DOHME LLC (US) 2023-08-16 — — EP disclosed
CN-116444501-A Quinazoline derivative, preparation method thereof, pharmaceutical composition and application 河北康泰药业有限公司 2023-07-18 — — CN disclosed
EP-4209485-A1 COMPOUND HAVING ANTITUMOR ACTIVITY AND USE THEREOF Innovstone Therapeutics Limited (CN) 2023-07-12 — — EP disclosed
US-20230159491-A1 Antimicrobial Compounds and Methods NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2023-05-25 — — US disclosed
CN-116113626-A Compound with anti-tumor activity and application thereof 上海翊石医药科技有限公司 2023-05-12 — — CN disclosed
US-11207312-B2 Metallo-beta-lactamase inhibitors and methods of use thereof MERCK SHARP & DOHME CORP. (US) 2021-12-28 — — US disclosed
US-20200281913-A1 Metallo-Beta-Lactamase Inhibitors and Methods of Use Thereof MERCK SHARP & DOHME CORP. (US) 2020-09-10 — — US disclosed
WO-2019018186-A1 METALLO-BETA-LACTAMASE INHIBITORS AND METHODS OF USE THEREOF MERCK SHARP & DOHME CORP. (US) 2019-01-24 — — WO disclosed
US-8551981-B2 Furo[3,2-d]pyrimidine compounds ABBVIE INC. (US) 2013-10-08 — — US disclosed
US-20120122846-A1 FURO[3,2-d]PYRIMIDINE COMPOUNDS ABBOTT LABORATORIES (US) 2012-05-17 — — US disclosed
US-7964613-B2 (S)-3-amino-1-(4-bromo-5-isoquinolinesulfonyl)pyrrolidine; inhibits phosphorylation of myosin regulatory light chain; for spinal canal stenosis, spinal cord injury, rheumatoid arthritis, multiple sclerosis; Rho kinase inhibitors ASAHI KASEI PHARMA CORPORATION (JP) 2011-06-21 — — US disclosed
EP-2130828-A1 SULFONAMIDE DERIVATIVE Asahi Kasei Pharma Corporation (JP) 2009-12-09 — — EP disclosed
US-20090048223-A1 Sulfonamide compound ASAHI KASEI PHARMA CORPORATION (JP) 2009-02-19 — — US disclosed
EP-0674623-B1 BICYCLIC FIBRINOGEN ANTAGONISTS SMITHKLINE BEECHAM CORP (US) 2003-04-09 — — EP disclosed
US-6403578-B1 ANTICOAGULANTS, CARDIOVASCULAR DISORDERS SMITHKLINE BEECHAM CORPORATION 2002-06-11 — — US disclosed
EP-0701568-A1 NEW PEPTIDE DERIVATIVES Astra Aktiebolag (SE) 1996-03-20 — — EP disclosed
EP-0674623-A1 BICYCLIC FIBRINOGEN ANTAGONISTS SMITHKLINE BEECHAM CORPORATION (US) 1995-10-04 — — EP disclosed
WO-1994014776-A2 BICYCLIC FIBRINOGEN ANTAGONISTS SMITHKLINE BEECHAM CORPORATION (US) 1994-07-07 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230159491-A1 Antimicrobial Compounds and Methods MPO, NISCH, RPN2 CA1 4525/4885CA2 2151/4885CA7 1619/4885
US-20120122846-A1 FURO[3,2-d]PYRIMIDINE COMPOUNDS CDK2, DPYD, CDK3 CA1 4308/4885CA2 3413/4885CA7 4290/4885
US-20200281913-A1 Metallo-Beta-Lactamase Inhibitors and Methods of Use Thereof MLX, MMP12, SLC11A2 CA1 431/4885CA2 279/4885CA7 174/4885
US-20240336593-A1 Compound Having Antitumor Activity And Use Thereof PRMT5, PRMT1, PRMT6 CA1 3988/4885CA2 4573/4885CA7 3922/4885
US-11207312-B2 Metallo-beta-lactamase inhibitors and methods of use thereof MLX, MMP12, SLC11A2 CA1 431/4885CA2 279/4885CA7 174/4885
US-20090048223-A1 Sulfonamide compound ALK, AKT1, ARAF CA1 1496/4885CA2 163/4885CA7 904/4885
US-12503452-B2 Antimicrobial compounds and methods MPO, NISCH, RPN2 CA1 4525/4885CA2 2151/4885CA7 1619/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.